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Visceral metastasis is widely considered a prognostic factor for overall survival of men with 
metastatic castration-sensitive prostate cancer (mCSPC) and has been historically 
managed with androgen deprivation therapy (ADT). More recently, this therapeutic 
scenario has been enriched by the possibility to integrate ADT with chemotherapy or novel 
androgen-signalling–targeted inhibitors. In order to define the effect of 
chemotherapy/androgen-signalling–targeted inhibitors plus ADT, we performed a pooled 
analysis on patients with mCSPC and visceral metastases revealing that survival was 
significantly improved in patients without visceral metastasis (HR=0.64 95%CI: 0.56-0.74; 
p<0.01) compared with men with visceral metastases (HR=0.68; 95%CI: 0.51-0.91; 
p<0.01). Although several limitations do not allow to draw definitive conclusions, our 
analysis confirms the efficacy of chemotherapy/androgen-signalling–targeted inhibitors in 
combination with ADT also in mCSPC with visceral metastases. In the absence of specific 
randomized controlled trials, symptoms, toxicity, cost, patients’ preference and clinical 
experience should guide the decision to add chemotherapy or androgen receptor-targeted 




Metastatic castration-sensitive prostate cancer (mCSPC) accounts for lesser than 10% of 
patients of all new prostate-cancer [1]. Although mCSPC has been historically managed 
with androgen deprivation therapy (ADT) through medical or surgical castration, more 
recently its therapeutic scenario has been enriched by the possibility to integrate ADT with 
chemotherapy or novel androgen-signalling–targeted inhibitors. From 2015, the addition of 
docetaxel to ADT for men with high-volume mCSPC has been considered the gold 
standard [2], as well as abiraterone acetate plus ADT have also improved overall survival 
in mCSPC [3,4], regardless of the burden of disease [5]. Similarly, apalutamide and 
enzalutamide were evaluated with interesting results in different phase III randomized trials 
[6-8]. All these studies showed a survival advantage in favour of novel androgen- 
signalling–targeted inhibitors although there is the need for prognostic factors to better 
stratify the patients considering that another strategy with a combination of chemotherapy 
to ADT [9] is available, and a direct comparison between all these approaches (docetaxel 




Visceral metastasis is widely considered a prognostic factor for overall survival of men with 
mCSPC. Data from different phase III trial suggest that visceral metastases (mainly lung or 
liver metastasis) account for less than 20% of patients with mCSPC [10]. Treating men 
with visceral metastases from de-novo’ mCSPC is considered an interesting challenge as 
no study reported a direct comparison from docetaxel + ADT versus novel androgen- 
signalling–targeted inhibitor plus ADT. 
 
From 2015, the addition of docetaxel to ADT has been investigated in three different phase 
III trials: the CHAARTED, the GETUG-AFU15 and the STAMPEDE (an arm of docetaxel) 
trials [9,11,12]. Docetaxel (Taxotere) is a member of the taxanes family which promotes 
aggregation of microtubules and the consequent inhibition of microtubule depolymerization 
tubulin, leading to the M-phase cell-cycle arrest and apoptosis through B-cell lymphoma 
(Bcl-2) phosphorylation [13]. The TAX 327 clinical trial was the first study to report efficacy 
of docetaxel for prostate cancer patients: in this study, 1006 patients refractory to the 
hormonal treatment were randomized to receive either docetaxel versus standard of care 
(SOC) mitoxantrone. Patients administered with docetaxel showed a higher survival rate 
than those administered with SOC, namely 18.9 months versus 16.5 months respectively 
(P=0.009) [14]. In the recent past, the CHAARTED randomized trial recruited 790 
metastatic prostate cancer patients to receive ADT plus docetaxel or ADT alone. Patients 
with high-volume disease (bone metastasis only) reported a hazard ratio of 0.64 (0.46 – 
0.89) while patients with visceral metastasis - observed in the 14% of patients in the 
experimental arm and 17% of patients in the control arm – reported a significant hazard 
ratio of 0.52 (0.25 – 1.07). In the GETUG-AFU15 trial, visceral metastases were observed 
in the 15% of men in the experimental arm and 12% of men in the control arm. However, 
the hazard ratios observed for GETUG-AFU15 study were 1.06 (0.41 – 2.75) for patients’ 
group with no bone metastasis and 1.01 (0.74 – 1.38) for the patients’ group diagnosed 
with bone metastasis. The STAMPEDE trial, which enrolled fewer patients with visceral 
metastases - liver metastases and lung metastases were reported in approximately 3% of 
all patients evaluated - a confirmed hazard ratio of 0.95 (0.62 – 1.47) was observed for 
patients with no metastatic lesions and a hazard ratio of 0.76 (0.62 – 0.92) for the 
metastatic patient group. 
The efficacy of androgen-signalling–targeted inhibitors plus ADT for patients with visceral 
metastases has been tested in several studies. The steroids abiraterone acetate (AA) and 
 
prednisone are administered together to inhibit CYP17 and zeroing the synthesis of 
androgens. Normally, CYP17 promotes the conversion of progesterone and pregnenolone 
to testosterone precursors; its inhibition leads to the decrease of cortisol levels and the 
compensatory rise of adrenocorticotropic hormone (ACTH) which, in turn, is hampered by 
the concomitant administration of steroids [15]. The COU-AA-301 study has been a 
cornerstone for the AA clinical approval: 1195 patients with prostate cancer were randomly 
assigned to receive either 1000 mg of AA or placebo with a prolonged OS for abiraterone 
acetate group (14.8 months vs. 10.9 months, HR = 0.65) [16]. More recently, the addition 
of abiraterone acetate and prednisone to ADT in CSPC has been investigated in two large 
trials: LATITUDE and STAMPEDE (abiraterone acetate arm) [3,4]. In the LATITUDE trial, 
where 1199 patients were randomly assigned to receive either ADT plus AA (1000 mg 
daily) or ADT plus dual placebos, the patients group with no visceral metastasis reported a 
final hazard ratio of 0.66 (0.53 – 0.82) whereas the patients’ group with visceral metastasis 
- nearly 20% of patients - reported a significant hazard ratio of 0.51 (0.33 – 0.79).  
Although the total median overall survival (OS) was 32 months in the placebo arm and not 
reached for the abiraterone arm (Table 1), the hazard ratio was in favour of patients with 
visceral metastases (0.51 versus 0.66). 
Enzalutamide has been investigated in two randomized trials for men with mCSPC 
(ENZAMET and ARCHES) [6,8]. Enzalutamide (Xtandi®) is a second-generation 
androgen receptor (AR) inhibitor which prevents androgen binding to the AR, activated AR 
nuclear translocation and its binding to the DNA, resulting in significant impairment of the 
AR signalling pathways at different stages [17]. In the first place, enzalutamide showed a 
meaningful lower risk of metastasis in the phase III PROSPER clinical trial where 1401 
non-metastatic prostate cancer patients were randomized 2:1 to receive 160 mg 
enzalutamide or placebo once daily. The median metastasis-free survival was 36.6 versus 
14.7  months  among patients  administered  with  enzalutamide  and  placebo respectively 
 
[18]. In the ENZAMET clinical study, a total of 1125 metastatic hormone-sensitive prostatic 
adenocarcinoma patients were enrolled. Patients with no metastasis who received 
enzalutamide benefited the most with a hazard ratio of 0.62 (0.47 – 0.82) whereas among 
patient with visceral metastasis - about 10% of patients - reported a hazard ratio of 1.05 
(0.54 – 2.02). In the ARCHES trial, a total of 1150 men diagnosed with prostate cancer – 
no patients with visceral metastases – were randomly assigned 1:1 to receive 
enzalutamide (160 mg/day) or placebo For patients with disease localization at baseline at 
bone only, soft tissue only and bone plus soft tissue the hazard ratios observed were 0.33 
( 0.22 – 0.49), 0.42 (0.15 – 1.20) and 0.42 (0.30 – 0.60) respectively [19]. 
Apalutamide is another novel non-steroidal antiandrogen agent which binds directly to the 
ligand-binding domain of the AR and, similarly to the enzalutamide, stops the AR 
translocation, DNA binding and the consequent androgen-receptor-mediated transcription 
[20]. Apalutamide agent firstly showed significant efficacy in the phase III SPARTAN trial 
where a total of 1207 non-metastatic prostate cancer patients were randomized 2:1 to 
receive apalutamide or placebo in combination with ADT [20]. Patients administered with 
apalutamide  reported statistically significant longer  metastasis-free  survival  (40.5 versus 
16.2 months) [HR = 0.28 (95% CI = 0.23-0.35) [20]. Afterwards, apalutamide has been 
tested against standard ADT in the TITAN trial [7] where 525 patients were randomly 
assigned to apalutamide group and 527 to the placebo group. Among the patients’ group 
with only bone metastasis at baseline and no visceral metastasis, the hazard ratio was 
0.63 (0.56-0.74). The patients’ group with visceral disease and bone metastasis at 
baseline - about 10% of patients had lung metastases and more than 2% of patients had 
liver metastases - reached a hazard ratio of 0.99 (0.55–1.77) 
 
 
In order to define the effect of chemotherapy/androgen-signalling–targeted inhibitors plus 
ADT, we performed a pooled analysis on patients with mCSPC and visceral metastases 
 
with all available data; therefore, data from LATITUDE, ENZAMET, TITAN and 
CHAARTED trials were analysed [3,6,7,9] (Table 1). A pooled analysis based on the 
presence of visceral metastasis revealed that survival was significantly improved in 
patients without visceral metastasis (HR=0.64 95%CI: 0.56-0.74; p<0.01 Figure 1), as well 
as men with visceral metastases (HR=0.68; 95%CI: 0.51-0.91; p<0.01 Figure 1). 
The presence of visceral metastases in CSPC is generally related to a poor prognosis. It 
has been estimated that up to 15% of de novo mHSPC patients had visceral metastases 
at the diagnosis [13]. Visceral metastases are one of the three criteria to define both high- 
volume CSPC (used to decide patients to treat with chemotherapy + ADT) and high-risk 
CSPC (used to decide to treat patients with abiraterone acetate + ADT). Interestingly, 
although high-volume disease and high-risk disease were mainly used to classify patients 
in the CHAARTED and LATITUDE studies [3,9], several retrospective studies validated 
their prognostic role in different populations of mCSPC [21-23]. Until 2015, men with 
visceral metastases from CSPC were treated with ADT alone; in our pooled analysis from 
literature data, we observed that the HR for survival of patients treated with 
chemotherapy/novel androgen-signalling–targeted inhibitors + ADT is similar regardless 
the presence of visceral metastases (patients with visceral metastases HR=0.68; patients 
without visceral metastasis HR=0.64 Figure 1). In fact, the efficacy and safety of 
docetaxel, as well as the efficacy and safety of novel androgen-signalling–targeted 
inhibitors, are well described in patients with visceral metastases from prostate cancer [24- 
25]. Based on these data, there is a strong rationale to add chemotherapy/novel 
androgen-signalling–targeted inhibitors in patients with de-novo metastatic CSPC with 
visceral metastases. One of the main questions still pending is which approach between 
chemotherapy and androgen-signalling–targeted inhibitors in addition to standard ADT is 
better for metastatic mCSPC with visceral metastases. To the best of our knowledge, the 
 
most suitable treatment for these patients remains an evolving issue that requires further 
investigations in specific studies. 
Conclusion 
 
Although several limitations including the low number of studies evaluated, the literature- 
based approach rather than a patients-based metanalysis do not allow to draw definitive 
conclusions, our analysis confirm the efficacy the use a novel treatment option in 
combination with ADT also in mCNPC with visceral metastases. Unfortunately, the best 
strategy (chemotherapy or AR-targeted therapy) for patients with visceral metastases, 
currently driven by symptoms, toxicity, cost, patients’ preference and clinical experience, 
still needs to be identified. 




Figure1. Subgroup analysis for overall survival of chemotherapy/novel androgen-signalling–targeted inhibitor 
+ ADT according to the presence of visceral metastases. 
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Table 1. Characteristics of the analysed trials and events according to the presence of 
visceral metastases. 
 
Trial Drug Overall survival 
Number of events 
/Number of Patients 
Experimental arm 
Number of events 
/Number of Patients 
Control arm 
Visceral Metastases 
LATITUDE Abiraterone Acetate 52/114 70/114 
ENZAMET Enzalutamide 18/62 18/67 
TITAN° Apalutamide 20/56 25/72 
CHARTEED°° Docetaxel NR NR 
No visceral metastases 
LATITUDE Abiraterone Acetate 223/483 273/488 
ENZAMET Enzalutamide 84/501 125/495 
TITAN° Apalutamide 55/236 64/258 
CHARTEED Docetaxel NR NR 
° Include men with bone metastasis 
°° Visceral metastases with or without bone metastases 
NR Not reported 
"Number of events Experimental (control) arm" should be "Number of events Experimental /Number of 
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